{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-070230","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.135647+00:00","generated_at":"2026-06-07T13:05:55.419365+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Rani Therapeutics announces preclinical data on oral triagonist and updates on pipeline milestones","bullets":["Preclinical study of incretin triagonist (GLP-1, GIP, glucagon) showed similar weight loss and lipid reduction via endoscope vs SC; no serious adverse events.","RT-102 (teriparatide for osteoporosis) Phase 2 trial expected to start in 2024.","Topline results from RT-111 Phase 1 (ustekinumab biosimilar) expected Q1 2024.","RaniPill HC development expected ready for Phase 1 trials in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-070230","json":"https://secwatch.observer/filing/0000950170-23-070230.json","markdown":"https://secwatch.observer/filing/0000950170-23-070230.md","text":"https://secwatch.observer/filing/0000950170-23-070230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023070230/0000950170-23-070230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023070230/rani-20231214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:05:55.419365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}